Robert Zerbib

Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis

Julien Carvelli, Olivier Demaria, Frédéric Vely et al. · Nature · 2020 · 549 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

Don M. Benson, Adam D. Cohen, Sundar Jagannath et al. · Clinical Cancer Research · 2015 · 176 citations

Life Sciences, Immunology, Pharmacology +17

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al. · The Lancet Respiratory Medicine · 2022 · 142 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +12

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

Norbert Vey, Lionel Karlin, Sophie Sadot‐Lebouvier et al. · Oncotarget · 2018 · 136 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

Martin Kropff, H Baylon, Tadeusz Robak et al. · Haematologica · 2011 · 55 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11